Metabolic surgery may protect against admission for COVID-19 in persons with nonalcoholic fatty liver disease.

ABSTRACT:

Background

SARS-CoV-2 (COVID-19) disease causes significant morbidity and mortality through increased inflammation and thrombosis. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are states of chronic inflammation and indicate advanced metabolic disease.

Objective

The purpose of this observational study was to characterize the risk of hospitalization for COVID-19 in patients with NAFLD/NASH and evaluate the mitigating effect of various metabolic treatments.

Setting

Retrospective analysis of electronic medical record data of 26,896 adults from a 12-hospital Midwest healthcare system with a positive COVID-19 polymerase chain reaction (PCR) test from March 1, 2020, to January 26, 2021.

Methods

Variable selection was guided by the l

SUBMITTER: Tignanelli CJ 

PROVIDER: S-EPMC8238640 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature